Impact of Respiratory Syncytial Virus (RSV) in Adults 60 Years and Older in Spain

被引：0
作者：
Ruiz, Sara Jimeno [1 ,2 ,3 ]
Pelaez, Adrian [3 ,4 ,5 ]
Gomez, Angeles Calle [1 ,2 ,3 ]
Garcia-Lomas, Mercedes Villarreal [3 ,6 ]
Martinez, Silvina Natalini [1 ,2 ,3 ]
机构：
[1] Hosp HM Puerta Sur, HM Hosp, Dept Pediat, Madrid 28938, Spain
[2] HM Hosp, Unidad Vacunas, Madrid 28938, Spain
[3] Univ Camilo Jose Cela, HM Hosp, Fac Ciencias Salud, Madrid 28692, Spain
[4] Fdn Invest HM Hosp, Dept Unidad Anal Datos, Madrid 28938, Spain
[5] Inst Salud Carlos III ISCIII, Ctr Invest Red Enfermedades Resp CIBERES, Madrid 28029, Spain
[6] Hosp HM, Hosp HM Torrelodones, Dept Med Interna, Madrid 28250, Spain
来源：
GERIATRICS | 2024年 / 9卷 / 06期
关键词：
respiratory syncytial virus; respiratory viruses; elder population; hospitalization; ICU admission; mortality; INFECTIONS;
D O I：
10.3390/geriatrics9060145
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
Background/Objectives: Respiratory illnesses frequently lead to hospitalization in adults aged 60 and older, especially due to respiratory viral infectious (RVI). This study investigates hospitalization patterns and characteristics of RVI at HM Hospitals from October 2023 to March 2024; Methods: We retrospectively explored hospitalizations of patients aged 60 years and older with RVIs, gathering data on demographics, clinical profiles, comorbidities, and treatments. Outcomes included hospitalization, ICU admissions, and mortality, and independent factors associated with outcomes were identified using a multi-state model; Results: From October 2023 to March 2024, from a total of 3258 hospitalizations, 1933 (59.3%) were identified as positive for RVIs. Overall, SARS-CoV-2 was the most prevalent (52.6%), followed by influenza (32.7%), and RSV (11.8%). Most RVI involved single infections (88.2%). Hospitalization rates increased with age for SARS-CoV-2 (333.4 [95% CI: 295.0-375.2] to 651.6 [95% CI: 532.1-788.4]), influenza (169.8 [95% CI: 142.6-200.7] to 518.6 [95% CI: 412.1-643.1]), and RSV (69.2 [95% CI: 52.2-90.0] to 246.0 [95% CI: 173.8-337.5]), with SARS-CoV-2 showing the highest rate, followed by influenza and RSV. In the multi-state model, RSV infection significantly increased ICU admission risk (HR: 2.1, 95%, p = 0.037). Age on admission (HR: 1.1, 95%, p < 0.001) and Charlson score (HR: 1.4, 95%, p = 0.001) were associated with transitioning from admission to death. ICU to death risks included age at admission (HR: 1.7, 95%, p < 0.001); Conclusions: RVI in adults 60 years and older are associated with high hospitalization and mortality rates, primarily driven by influenza and SARS-CoV-2, followed by RSV. Age and comorbidities significantly impact disease severity, emphasizing the need for targeted prevention and management strategies for RSV in this vulnerable population.
引用
收藏
页数：14
相关论文
共 35 条
  • [1] Soriano J.B., Pelaez A., Fernandez E., Moreno L., Ancochea J., The Emergence of COVID-19 as a Cause of Death in 2020 and its Effect on Mortality by Diseases of the Respiratory System in Spain: Trends and Their Determinants Compared to 2019, Arch. Bronconeumol, 58, pp. 13-21, (2022)
  • [2] Trias-Llimos S., Riffe T., Bilal U., Monitoring life expectancy levels during the COVID-19 pandemic: Example of the unequal impact of the first wave on Spanish regions, PLoS ONE, 15, (2020)
  • [3] Gonzalez-Granado L.I., Martin-Nalda A., Alsina L., Neth O., Santamaria M., Soler-Palacin P., Infecciones por virus respiratorio sincitial que requieren hospitalización en pacientes con inmunodeficiencias primarias, An. De Pediatría, 96, pp. 492-500, (2022)
  • [4] Huang G., Guo F., Liu L., Taksa L., Cheng Z., Tani M., Zimmermann K.F., Franklin M., Silva S.S.M., Changing impact of COVID-19 on life expectancy 2019–2023 and its decomposition: Findings from 27 countries, SSM-Popul. Health, 25, (2024)
  • [5] Heppe-Montero M., Gil-Prieto R., del Diego Salas J., Hernandez-Barrera V., Gil-de-Miguel A., Impact of respiratory syncytial virus and influenza virus infection in the adult population in Spain between 2012 and 2020, Int. J. Environ. Res. Public Health, 19, (2022)
  • [6] Binder W., Thorsen J., Borczuk P., RSV in adult ED patients: Do emergency providers consider RSV as an admission diagnosis?, Am. J. Emerg. Med, 35, pp. 1162-1165, (2017)
  • [7] Falsey A.R., McElhaney J.E., Beran J., Van Essen G.A., Duval X., Esen M., Galtier F., Gervais P., Hwang S.J., Kremsner P., Et al., Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness, J. Infect. Dis, 209, pp. 1873-1881, (2014)
  • [8] Staadegaard L., Caini S., Wangchuk S., Thapa B., de Almeida W.A.F., de Carvalho F.C., Fasce R.A., Bustos P., Kyncl J., Novakova L., Et al., Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries, Influenza Other Respir. Viruses, 15, pp. 732-741, (2021)
  • [9] Borchers A.T., Chang C., Gershwin M.E., Gershwin L.J., Respiratory syncytial virus—A comprehensive review, Clin. Rev. Allergy Immunol, 45, pp. 331-379, (2013)
  • [10] Recomendaciones de Utilización de Nirsevimab Frente a Virus Respiratorio Sincitial Para la Temporada 2023–2024, (2023)
1234